首页> 外文期刊>Journal of clinical laboratory analysis. >CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis
【24h】

CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis

机译:Circrnas作为诊断乳腺癌的有前途的生物标志物:更新的荟萃分析

获取原文
           

摘要

Background Circular RNAs (circRNAs) have been identified to be involved in onset and progression of multiple malignant tumors. The present study aimed to systematically evaluate the diagnostic values of circRNAs in breast cancer. Methods The PubMed, Web of Science, Embase, CNKI, and Wanfang online databases were searched for the relevant studies before December 31, 2020. Statistical analysis of the diagnostic tests was performed based on STATA 16.0, Meta-DiSc 1.4, and RevMan 5.3?software. The threshold effect and publication bias were measured by the Spearman correlation and Deeks’ funnel plot asymmetry test, respectively. Results Twenty-one studies from 13 articles were included in this meta-analysis. The pooled sensitivity and specificity were 0.77 and 0.71, respectively. The pooled positive likelihood ratio (PLR), negative likelihood ratio (NLR), and overall diagnostic odds ratio (DOR) were 2.6, 0.33, and 8, respectively. Furthermore, the area under the summary receiver operator characteristic curve was 0.80. In addition, down-regulated circRNAs achieved a diagnostic performance higher than up-regulated circRNAs, with area under curve (AUC) values of 0.81 and 0.74, respectively. Studies based on tissue samples presented better diagnostic accuracy than those based on plasma samples, with AUC values of 0.80 and 0.67. In addition, two circRNAs, including circ_0001073 and circTADA2A-E5/E6, showed higher diagnostic values, with AUC value of 0.990 and 0.937, respectively. According to the results of meta-regression, the case size ( p 0.05) might be the source of the heterogeneity. Conclusion CircRNAs exhibited a high diagnostic value for breast cancer and may function as potential diagnostic biomarkers for breast cancer.
机译:背景技术已经鉴定出圆形RNA(CircRNA)涉及多种恶性肿瘤的发作和进展。本研究旨在系统地评估Circrnas在乳腺癌中的诊断价值。方法在2020年12月31日前搜索了PubMed,Embase,CNKI和WANFANG网上数据库的PUBMED,EMBASE,CNKI和WANFANG网上数据库。诊断测试的统计分析是基于Stata 16.0,META-DISC 1.4和Revman 5.3执行的诊断测试?软件。通过Spearman相关和Deeks漏斗曲线不对称试验测量阈值效应和出版物偏压。结果此荟萃分析中包含来自13篇文章的二十一项研究。合并的敏感性和特异性分别为0.77和0.71。汇集的正似然比(PLR),负似然比(NLR)和整体诊断量比(DOR)分别为2.6,0.33和8。此外,总结接收器操作员特征曲线下的区域为0.80。此外,下调CircrNA可以达到高于上调CircrNA的诊断性能,分别在曲线(AUC)值下的面积分别为0.81和0.74。基于组织样品的研究呈现比基于血浆样品的诊断精度更好,AUC值为0.80和0.67。此外,两个CircRNA,包括Circ_0001073和Circtada2A-E5 / E6,显示出较高的诊断值,分别为0.990和0.937的AUC值。根据元回归的结果,壳体尺寸(P <0.05)可能是异质性的来源。结论Circrnas对乳腺癌的诊断价值高,可用作乳腺癌的潜在诊断生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号